Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Prevalence of the metabolic syndrome in patients with borderline personality disorder: Results from a cross-sectional study

Kai G. Kahl*, Wiebke Greggersen, Ulrich Schweiger, Joachim Cordes, Christoph U. Correll, Helge Frieling, Chakrapani Balijepalli, Christian Lösch, Susanne Moebus

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Metabolic syndrome (MetS) is an important risk factor for the development of type-2 diabetes and coronary artery disease. We aimed to compare the MetS prevalence in patients with borderline personality disorder (BPD) with comparison subjects followed in primary care from a similar region. One hundred and thirty-five BPD patients according to DSM-IV diagnostic criteria were compared to 1009 subjects from primary care. We used the American Heart Association/National Heart, Lung and Blood Institute criteria to determine the rate of MetS. The age-standardized prevalence of MetS was more than double in patients with BPD compared to comparison subjects (23.3 vs. 10.6 %, p < 0.05). Regarding individual MetS criteria, hyperglycemia was significantly more prevalent in both genders (p < 0.05). Abdominal obesity (p < 0.05) and hypertriglyceridemia (p < 0.05) were significantly higher only in women with BPD. Within BPD patients, an increased rate of MetS was associated with higher BMI (p = 0.004), age (p = 0.03), treatment with second-generation antipsychotics (quetiapine, olanzapine and clozapine; p = 0.032), dysthymia (p = 0.031), panic disorder (p = 0.032), benzodiazepine dependency (p = 0.015) and binge eating disorder p = 0.02). Our results demonstrate an increased MetS rate, dysregulated glucose and lipid metabolism in patients with BPD. Cardiometabolic monitoring and careful screening for physical health conditions among people with BPD is warranted.

OriginalspracheEnglisch
ZeitschriftEuropean Archives of Psychiatry and Clinical Neuroscience
Jahrgang263
Ausgabenummer3
Seiten (von - bis)205-213
Seitenumfang9
ISSN0940-1334
DOIs
PublikationsstatusVeröffentlicht - 04.2013

Fördermittel

Conflict of interest Kai G. Kahl received Speaker Honoraries from Eli Lilly, AstraZeneca, Lundbeck and Servier. Helge Frieling receiced Speaker Honoraria from Servier. Christoph U, Correll has been a consultant and/or advisor to or has received honoraria from Actelion, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Eli Lilly, Intra-Cellular Therapeutics; Ortho-McNeill/Janssen/ J&J, GSK, Hoffmann-La Roche, Lundbeck, Medicure, Otsuka, Pfizer, Schering-Plough, Sepracor/Sunovion, Supernus, Takeda and Vanda. GEMCAS was supported by an unrestricted educational research grant by Sanofi Aventis Deutschland GmbH, Berlin, Germany.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen
  2. SDG 10 – Weniger Ungleichheiten
    SDG 10 – Weniger Ungleichheiten

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Prevalence of the metabolic syndrome in patients with borderline personality disorder: Results from a cross-sectional study“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren